0.0899  -0.01 (-10.1%)		08-14 16:00
Open: 0.095 High: 0.1042 Volume: 22,015,006		Pre. Close: 0.1 Low: 0.087 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	17.22	1-year :	27.8
Resists	First :	14.74	Second :	23.8
Pivot price	4.46
Supports	First :	0.08	Second :	0.07
MAs	MA(5) :	4.62	MA(20) :	5.08
	MA(100) :	15.56	MA(250) :	44.93
MACD	MACD :	-1.1	Signal :	-1.4
%K %D	K(14,3) :	24.2	D(3) :	20.8
RSI	RSI(14): 44.5
52-week	High :	109.19	Low :	0.08

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ HUGE ] has closed below upper band by 48.3%. Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.35 - 5.38	5.38 - 5.4
Low:	4.35 - 4.38	4.38 - 4.4
Close:	4.54 - 4.58	4.58 - 4.61

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.

Mon, 12 Aug 2024
FSD Pharma Rebrands As Quantum BioPharma: Major Share Consolidation Announced - Benzinga

Mon, 12 Aug 2024
FSD Pharma changes its name to Quantum BioPharma - Green Market Report

Fri, 09 Aug 2024
Why FSD Pharma Stock Is Seeing Huge Gains - Benzinga

Fri, 09 Aug 2024
FSD Pharma Rebrands and Consolidates Shares - TipRanks

Fri, 09 Aug 2024
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team - Yahoo Finance

Fri, 09 Aug 2024
FSD Pharma Announces Share Consolidation and Name Change - Newsfile

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	1 (M)
Shares Float	1 (M)
Held by Insiders	9.7 (%)
Held by Institutions	2.6 (%)
Shares Short	3 (K)
Shares Short P.Month	2 (K)

EPS	-16.25
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	17.09
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-36.5 %
Return on Equity (ttm)	-63.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-14.4
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.29
PEG Ratio	0
Price to Book value	0.26
Price to Sales	0
Price to Cash Flow	-0.64

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.